Home › Pancreatic Cancer › Kentucky
Pancreatic Cancer clinical trials in Kentucky
13 studies for Pancreatic Cancer are looking for participants at sites in Kentucky.
Cities in Kentucky
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- University of Kentucky/Markey Cancer Center, Lexington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05372614A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- University of Kentucky Research Foundation, Lexington
- University of Kentucky Healthcare - Markey Cancer Center, Lexington
- University of Kentucky Medical Center, Lexington
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care, Edgewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07409272Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- University of Kentucky/Markey Cancer Center, Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06958328EXoPERT EMERALD Clinical Study
- Lexington VA Healthcare System, Lexington
- KCTL, Louisville
RecruitingObservational studyHealthy volunteers welcome
Ages 45 and older · All sexes · Updated Jul 1, 2026 · NCT07186296Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Flaget Memorial Hospital, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Hospital, Lexington
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06998940Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- University of Kentucky/Markey Cancer Center, Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT06807437A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- Ohio State University-Telemedicine, Lexington
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT06906562cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
- University of Kentucky, Lexington
Recruiting
Ages 18 and older · All sexes · Updated Dec 16, 2025 · NCT05391126Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
- University of Louisville, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT03484299American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
- University of Louisville, Louisville
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 25, 2025 · NCT02674100From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.